Spherix Global Insights
Survey: Halting neurodegeneration chief concern in Huntington’s disease
According to results of a recent survey, more than 80% of U.S.-based neurologists agreed that a major unmet need in confronting Huntington’s disease is halting neurodegeneration prior to the onset of symptoms.
US biosimilar market in 2023: Sea change or slow drip?
News pertaining to biosimilars came at a fast and furious pace in 2023.
Survey finds neurologists seek to minimize side effects of treatment in Parkinson’s
Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of symptoms without experiencing side effects, according to results of a new study.
Survey shows limited uptake with new anemia drugs
PHILADELPHIA — Results of a survey conducted in the U.S. and abroad showed that most nephrologists remain wary about prescribing hypoxia-inducible factor-prolyl hydroxylase inhibitors, according to a poster presentation at ASN Kidney Week.
Top in rheumatology: Barriers to paid family leave; risks of B-cell depleting therapies
The standard 12 weeks of paid family leave in the United States is often unavailable to health care providers. For them, the reality of paid leave is much different, experts said.
‘Comfort level’ driving divide between rheumatologists, nephrologists in lupus nephritis
Recent data has revealed a growing divide between rheumatologists and nephrologists in their therapeutic choices for patients with lupus nephritis, according to researchers from Spherix Global Insights.
‘Risk averse’ rheumatologists report declining JAK use, increased reliance on abatacept
The safety signals for cardiovascular events and malignancy associated with Janus kinase inhibitors in rheumatoid arthritis have led to rheumatologists increasingly reaching for abatacept instead, according to data.
AXS-07 effective against migraine pain in phase 3 INTERCEPT trial
Results of the phase 3 INTERCEPT trial showed that AXS-07, an oral agent for acute migraine treatment, was significantly more effective at preventing pain progression than placebo and eliminated migraine pain in approximately one-third of patients within 2 hours of dosing, according to a press release from the manufacturer.
Study shows long-term efficacy of erenumab for chronic migraine
A 52-week open label extension of a previous 12-week double-blind treatment study showed sustained efficacy and safety of erenumab for the treatment of chronic migraine.
Survey: COVID-19 has had little impact on nephrology practices
In a March 10 survey of 85 practicing nephrologists, just one nephrologist was treating a patient diagnosed with COVID-19 and 30% of surveyed nephrologists rated the federal government’s handling of the pandemic as unfavorable.